Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia.
We have recently demonstrated that selective inducible nitric oxide (NO) synthase (iNOS) inhibition with 1400W attenuated the hemodynamic and metabolic alterations affiliated with hyperdynamic porcine endotoxemia. In contrast to endotoxemia, limited evidence is available to document a relationship between NO and organ dysfunction in large animal bacteremic models. Therefore, using the same experimental setup, we investigated the role of selective iNOS blockade in porcine bacteremia induced and maintained for 24 h with a continuous infusion of live Pseudomonas aeruginosa. After 12 h of sepsis, animals received either vehicle (Control, n = 8) or continuous infusion of selective iNOS inhibitor, L-N6-(1-iminoethyl)-lysine (L-NIL; n = 8). Measurements were performed before, and 12, 18, and 24 h after P. aeruginosa infusion. L-NIL inhibited sepsis-induced increase in plasma nitrate/nitrite concentrations and prevented hypotension without affecting cardiac output. Despite comparable hepatosplanchnic macrocirculation, L-NIL blunted the progressive deterioration in ileal mucosal microcirculation and prevented mucosal acidosis. L-NIL largely attenuated mesenteric and hepatic venous acidosis, significantly improved P. aeruginosa-induced impairment of hepatosplanchnic redox state, and mitigated the decline in liver lactate clearance. Furthermore, the administration of L-NIL reduced the hepatocellular injury and prevented the development of renal dysfunction. Finally, treatment with L-NIL significantly attenuated the formation of 8-isoprostane concentrations, a direct marker of lipid peroxidation. Thus, selective iNOS inhibition with L-NIL prevented live bacteria from causing key features of metabolic derangements in porcine hyperdynamic sepsis. Underlying mechanisms probably include reduced oxidative stress with improved microcirculatory perfusion and restoration of cellular respiration.
Matejovic
Martin
M
Intensive Care Unit, 1st Medical Department, Charles University, Plzen, Czech Republic. matejovic@fnplzen.cz
Krouzecky
Ales
A
Martinkova
Vendula
V
Rokyta
Richard
R
Kralova
Hana
H
Treska
Vladislav
V
Radermacher
Peter
P
Novak
Ivan
I
D000818:Animals; D001158:Arteries / Q000378:metabolism; D016470:Bacteremia / Q000473:pathology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D019446:Endotoxemia / Q000473:pathology; D007413:Intestinal Mucosa / Q000473:pathology; D007668:Kidney / Q000378:metabolism; D007773:Lactates / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D052247:Nitric Oxide Synthase Type II; D018384:Oxidative Stress; D010100:Oxygen / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000378:metabolism*; D011773:Pyruvates / Q000378:metabolism; D018805:Sepsis / Q000378:metabolism; D013552:Swine; D013997:Time Factors
D007773:Lactates; C090663:N(6)-(1-iminoethyl)lysine; D011773:Pyruvates; C075750:8-epi-prostaglandin F2alpha; D009569:Nitric Oxide; D015237:Dinoprost; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D008239:Lysine; D010100:Oxygen